{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:26:49Z","timestamp":1761744409360,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jjcc.2016.10.009","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T14:01:34Z","timestamp":1480082494000},"page":"511-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial"],"prefix":"10.1016","volume":"69","author":[{"given":"Masataka","family":"Kajiwara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2016.10.009_bib0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1475-2840-8-23","article-title":"Postprandial hyperglycemia as an etiological factor in vascular failure","volume":"8","author":"Node","year":"2009","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0260","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(11)60614-4","article-title":"Type 2 diabetes across generations: from pathophysiology to prevention and management","volume":"378","author":"Nolan","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11886-012-0331-5","article-title":"Update on type 2 diabetes as a cardiovascular disease risk equivalent","volume":"15","author":"Kuusisto","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0270","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0275","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0280","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.298.7.765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0285","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0290","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0295","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0300","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0305","doi-asserted-by":"crossref","first-page":"d6898","DOI":"10.1136\/bmj.d6898","article-title":"Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials","volume":"343","author":"Hemmingsen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0310","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0315","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0320","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0325","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI30076","article-title":"The role of gut hormones in glucose homeostasis","volume":"117","author":"Drucker","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0330","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0335","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","article-title":"Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes","volume":"36","author":"Ferrannini","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0340","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0345","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0350","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4158\/EP.17.6.906","article-title":"Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program","volume":"17","author":"Henry","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0355","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1345\/aph.1Q024","article-title":"Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"45","author":"Pinelli","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0360","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4158\/EP12232.OR","article-title":"Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%","volume":"19","author":"King","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0365","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-9-6","article-title":"Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study","volume":"9","author":"Gill","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0370","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0375","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0380","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00125-005-0126-y","article-title":"Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans","volume":"49","author":"Meier","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0385","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsboll","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0390","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0395","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0400","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jjcc.2015.01.009","article-title":"Remote ischemic conditioning: current clinical perspectives","volume":"66","author":"Le Page","year":"2015","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0405","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jjcc.2015.09.002","article-title":"Ischemia-reperfusion injury is still a big hurdle to overcome for treatment of acute myocardial infarction","volume":"67","author":"Inoue","year":"2016","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0410","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","article-title":"Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury","volume":"53","author":"Timmers","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0415","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice","volume":"58","author":"Noyan-Ashraf","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0420","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0425","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/hrt.2010.219345","article-title":"Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease","volume":"98","author":"Read","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0430","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"Lonborg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0435","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1161\/CIRCINTERVENTIONS.112.968388","article-title":"Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia","volume":"5","author":"Lonborg","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0440","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0445","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2012.11.057","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury","volume":"699","author":"Hirata","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0450","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000381097","article-title":"Glucagon-like peptide-1 receptor activation does not affect re-endothelialization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of arterial injury","volume":"52","author":"Eriksson","year":"2015","journal-title":"J Vasc Res"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0455","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0460","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0465","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0470","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0475","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.numecd.2014.01.017","article-title":"Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials","volume":"24","author":"Monami","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0480","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.clinthera.2014.10.009","article-title":"Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure","volume":"36","author":"Clifton","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0485","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0490","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.diabres.2008.03.018","article-title":"Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes","volume":"81","author":"Seino","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0495","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.10.009_bib0500","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","article-title":"One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial","volume":"65","author":"Pratley","year":"2011","journal-title":"Int J Clin Pract"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508716302684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508716302684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:56:45Z","timestamp":1760273805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508716302684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0914508716302684"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2016.10.009","relation":{},"ISSN":["0914-5087"],"issn-type":[{"type":"print","value":"0914-5087"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2016.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2016.11.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}